Acute Lymphoblastic Leukemia Clinical Trials in Tianjin, Tianjin Municipality
15 recruitingTianjin, Tianjin Municipality, China
Showing 1–15 of 15 trials
Recruiting
Phase 1Phase 2
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
B Cell Precursor Acute Lymphoblastic Leukemia
Amgen281 enrolled86 locationsNCT04521231
Recruiting
Phase 1Phase 2
A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
Acute Lymphoblastic Leukemia
MSD R&D (China) Co., Ltd.203 enrolled11 locationsNCT05579132
Recruiting
Early Phase 1
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Chronic Lymphocytic Leukemia (CLL)B-cell Acute Lymphoblastic Leukemia (B-ALL)Autoimmune Hemolytic Anemia, AIHA+1 more
Grit Biotechnology28 enrolled2 locationsNCT07205315
Recruiting
Phase 3
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)Childhood Leukemia, Acute Lymphoblastic
Institute of Hematology & Blood Diseases Hospital, China150 enrolled24 locationsNCT07152041
Recruiting
Phase 2Phase 3
Newly-diagnosed Pediatric T-cell ALL Protocol
Acute Lymphoblastic LeukemiaChildhood Leukemia, Acute LymphoblasticT Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Institute of Hematology & Blood Diseases Hospital, China610 enrolled27 locationsNCT06855810
Recruiting
Phase 2Phase 3
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
Childhood Leukemia, Acute LymphoblasticB-cell Acute Lymphoblastic Leukemia (B-ALL)Acute Lymphoblastic Leukemia ALL
Institute of Hematology & Blood Diseases Hospital, China3,000 enrolled27 locationsNCT06882057
Recruiting
Phase 1Phase 2
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
B-cell Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.47 enrolled9 locationsNCT05667506
Recruiting
Phase 2
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Relapsed or Refractory Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.100 enrolled11 locationsNCT04684147
Recruiting
Phase 1
CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
Acute Myeloid LeukemiaB Acute Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT07106749
Recruiting
Phase 2Phase 3
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
Childhood Leukemia, Acute LymphoblasticB-cell Acute Lymphoblastic Leukemia (B-ALL)Acute Lymphoblastic Leukemia ALL
Institute of Hematology & Blood Diseases Hospital, China1,800 enrolled26 locationsNCT06764238
Recruiting
Phase 2
Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
B-cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT06608732
Recruiting
Phase 2
Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia ALL
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT06608342
Recruiting
Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
B-cell Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.200 enrolled10 locationsNCT06450067
Recruiting
Phase 2
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaRelapsed Pediatric ALL
Chongqing Precision Biotech Co., Ltd100 enrolled10 locationsNCT05334823
Recruiting
Phase 1Phase 2
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Acute Myeloid LeukemiaNon-Hodgkin LymphomaHematologic Malignancy+2 more
Shenzhen TargetRx, Inc.30 enrolled1 locationNCT06206174